Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy
Helicobacter, 04/17/2012Manfredi M et al.
Probiotics associated with Sequential therapy (ST) provide optimum therapeutic compliance compared with the placebo and, despite the need to take a larger number of tablets, they should be taken into consideration as an adjuvant to therapy for H. pylori infection. The addition of lactoferrin (LF) to the probiotics (PB) did not bring about any further improvements in compliance. As compared with the placebo, the eradication rate of ST did not improve by adding LF + PB or by using PB alone.
Over a period of 2 years, the authors randomized and divided 227 consecutive adult patients with H. pylori infection into three groups.
The patients were given ST with the addition of adjuvants, as follows: group A (ST + placebo), group B (ST + LF + PB), and group C (ST + PB).
The goal was to assess therapeutic compliance, so they prepared a questionnaire to help determine the severity of the side effects.
They also determined the eradication rates for the groups.
Patients with ST + placebo had the worst compliance as compared with the other two groups in terms of the absence of symptoms (p < .001 between B and A; p = .001 between C and A) and the presence of intolerable symptoms (p = .016 between B and A; p = .046 between C and A).
The differences between the values for the treated groups and those for the placebo group were statistically significant.
On the other hand, there was no statistically significant difference in compliance between groups B and C.
The eradication rate was similar for the three groups.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.